4C LABS Pitch DeckThe Worlds Finest Medical Cannabis on a Global Scale

This presentation contains confidential information, it is being delivered by 4C LABS SAS, (“4C Labs or the “Company”), to a select number of parties who may have an interest in pursuing business or financial relationships with 4C Labs. Nothing contained within this presentation is an offer to buy or sell securities or an offering of a product, services or fund, service or fund. An offer to buy or sell securities will only be accompanied by the appropriate documents including, but not limited to, a private memorandum that will contain, among other things, a listing of possible risk factors associated with the security. The information contained in this presentation have been made to ensure that it was obtained from sources deemed to be reliable. The Company does not guarantee that the information contained herein is accurate or complete and is not responsible for any errors or omissions, timeliness, or the results obtained from the use of this information. All information in this presentation is provided “as is” and without warranty or representation of any kind, express, or implied, oral or written.

•BY ACCEPTING THIS PRESENTATION, THE RECIPIENT AGREES TO KEEP CONFIDENTIAL ALL NON-PUBLIC INFORMATION CONTAINED HEREIN OR MADE AVAILABLE IN CONNECTION WITH ANY FURTHER INVESTIGATION OF THE COMPANY. THIS PRESENTATION SHALL NOT BE PHOTOCOPIED, REPRODUCED, OR DISTRIBUTED TO OTHERS AT ANY TIME WITHOUT THE PRIOR WRITTEN CONSENT OF THE COMPANY. ADDITIONAL INFORMATION MAY BE MADE AVAILABLE TO PARTIES WHO HAVE EXECUTED A WRITTEN CONFIDENTIALITY AGREEMENT.

•In no event will 4C Labs, its members, partners, agents or employees be liable to you or anyone else for any decision made or action taken in reliance on the information in this document or for any consequential, special or similar damages, even if advised of the possibility of such damages. You should conduct your own due diligence with respect to any and all information related to this document and are not entitled to reply solely on the information presented herein. Further, 4C Labs is under no obligation to update the material or information presented herein even if they later become aware that such information or material is no longer accurate or true. Recipient assumes all risk in, and 4C Labs will not be liable for any damages arising out of Recipient’s use of information including, without limitation, business decisions made or inferences drawn by Recipient in reliance on the information or the fact of disclosure of the information.

•BY ACCEPTING THIS PRESENTATION, THE RECIPIENT AGREES TO KEEP CONFIDENTIAL ALL NON-PUBLIC INFORMATION CONTAINED HEREIN OR MADE AVAILABLE IN CONNECTION WITH ANY FURTHER INVESTIGATION OF THE COMPANY. THIS PRESENTATION SHALL NOT BE PHOTOCOPIED, REPRODUCED, OR DISTRIBUTED TO OTHERS AT ANY TIME WITHOUT THE PRIOR WRITTEN CONSENT OF THE COMPANY. ADDITIONAL INFORMATION MAY BE MADE AVAILABLE TO PARTIES WHO HAVE EXECUTED A WRITTEN CONFIDENTIALITY AGREEMENT.

Disclaimer

Why 4C LABS? The UK & European medical markets are set for significant growth. 4C Labs is positioned to capitalize on this growth.

10b 30b

40b

20b

1b

Potential European Medical Cannabis

Market

The European medical market is set to surpass €37.5 billion.

www4clabs.ca

Our MissionTo produce and distribute world-class, medical grade cannabis products with unmatched consistency, quality and safety.

Our PrinciplesWe recognize that success depends on the synergy of innovation, knowledge, expertise and collaboration.

We aim to economically and socially benefit the communities where we work.

We know that superior genetics and innovative techniques are required for the highest quality medical products.

We understand that education is a key component to developing and expanding distribution networks in Europe and markets around the world.

www4clabs.ca

4C Labs has done the ground-work to ensure we have the capabilities to grow, manufacture and deliver the best possible product.

We have:

• Forged solid partnerships in Colombia, Malta, and the UK to deliver GMP certified pharmaceutical product for the medical market.

• Secured a full suite of licenses for cultivating and extracting cannabis in Colombia.

• Completed the first and only application for producing Medical Cannabis in Guernsey.

• Developed a partnership with a medical device manufacturer.

• Access to a potential listing in Guernsey (The International Stock Exchange) which provides a path to a simultaneous inter-listing on the TSX-V + Borse Frankfurt (Frankfurt Stock Exchange).

• Developed a solid understanding of the direction of the Global Cannabis markets.

4C LABS - Premium Quality, Industrial Scale and Globally

Focused

Our Products

We formulate our products to target specific diseases such as arthritis, cancer, MS, epilepsy and sleep disorders..

www.4clabs.ca

Premium, medical grade EU GMP certified flowers and extracts.

Finished certified pharma products with our pharma

partners.

Global: The global medical cannabis market was US$13b in 2018 and is expected to reach US$44.4b by 2024, exhibiting a CAGR of 22.9% during 2019-2024.

Europe: The EU estimates that there are currently 3m adults who consume daily or near daily. Germany is the largest market with 180,000 patients (over 500,000) by 2024.

UK: UK estimates there are 4.7m cannabis users and they have the highest prices in Europe. It is expected to be one of the fastest growing markets with over 1 million patients over the next 10 years. www.4clabs.ca

Market Opportunities

8

• Cultivation, import and distribution hub.• 6 acres of land with 30,000 sq. ft of greenhouses.• 10,000 sq. ft warehouse and processing facility.• 0% import tax on goods from Colombia.• 0% corporate tax.

MaltaWorld-class manufacturing with distribution to Europe

• Constructing manufacturing facility• License issued in June 2019.• 4C LABS owns 33% of Malta license.

ColombiaProducing premium low-cost medical cannabis

• Fully licensed in 2019 to grow, extract, formulate and export.

GuernseySpecialty EU GMP Flower production, Specialty warehouse

4C LABS Global Operations

www4clabs.ca

Understanding our Global Supply Chain

GROWING EXTRACTING MANUFACTURING DISTRIBUTION

CBD is grown in ColombiaSend finished product to locations in South America, including Brazil

CBD is extracted in Colombia

Send to Colombian pharmaceutical manufacturer

Colombia to South America

GROWING EXTRACTING DISTRIBUTION POINT OF SALE

CBD is grown in Colombia CBD is extracted in Colombia

Send finished product to UK distributor

Product is sent to The Medical Cannabis Clinics

in the UK

Colombia to UK

www4clabs.caca

GROWING EXTRACTING MANUFACTURING DISTRIBUTION

Medical flower grown in Guernsey

Send finished product to UK and German clinicsExtract in Guernsey

Formulate and package in Guernsey

Guernsey to UK and Germany

Understanding our Global Supply Chain

www4clabs.caca

0.2 0.3 0.2

3.6

1.6 1.8

7

55.5

0

1

2

3

4

5

6

7

8

Colombia Bulk CBD/CBGExports

Colombia Finished PharmaProducts for Export toInternational Markets

Guernsey Medical Flower

2020 2021 2022

1.50.46

14.3

2.6

17.5

7.5

0

2

4

6

8

10

12

14

16

18

20

Gross Revenue EBITDA

2020 2021 2022

Mill

ions

Mill

ions

Revenue Projections 2020-2022

www4clabs.ca

www.4clabs.ca

4C Labs has an agreement in the UK to supply The Medical Cannabis Clinics. 4C LABS anticipates a 40% share of product supplied to the Medical Cannabis Clinics.

$0.00

$10.00

$20.00

$30.00

$40.00

$50.00

$60.00

$70.00

$80.00

Year 1 Year 5 Year 7 Year 10

Mill

ions

Market Forecast (UK) – 2020-2025

The Cannabis Medical Clinics (UK)

Year # of Patients

Sept 2020 4800

Dec 2020 7027

Dec 2021 14000

Dec 2022 26000

Dec 2023 52000

Dec 2024 74000

Dec 2025 167500

Market Over TimeOther Private Clinics

Year # of PatientsSept 2020 3800

Dec 2020 8500

Dec 2021 16000

Dec 2022 29000

Dec 2023 55000

Dec 2024 88000

Dec 2025 212000

COLOMBIA

Complete seeds and go into production

GUERNSEY

Complete warehouse facility in Guernsey

COLOMBIA

Construct and certify low cost medical extraction facility

GUERNSEYExpand flower production for

UK and German sales

4C LABS Strategic Plan – 2020

www.4clabs.ca

0

1000

2000

3000

4000

5000

6000

Year 1 Year 5 Year 7 Year 10

kg./m

onth

Forecasted Consumption

www.4clabs.ca

Deep Dive UK

The Medical Cannabis Clinics

Dr. Barnes, our Chief Medical Advisor and partner, works closely with a group of private clinics called The Medical Cannabis Clinics. The Medical Cannabis Clinics group plans to open 15 clinics in 2020. Three of the clinics have already been licensed. Other private clinics are also slated to open.

0

100,000

200,000

300,000

400,000

500,000

600,000

700,000

800,000

Year 1 Year 5 Year 10

Patie

nts

Patient Growth

4C LABS Milestones – 2018-2020

www.4clabs.ca

2018

• Identified shortcomings in Colombian plans and areas of production

• Identified location suitable for production and secured property

• Created Colombian company (4Clabs SAS)

• Acquired all licenses• Start search for strategic partners• Applied for process and importation

licenses in Malta (with Hoshi International)

2019

• Began negotiations with several Colombian groups

• Malta licenses issued• Signed LOI’s with several Colombia

groups• Final Colombian licenses issued• Applied for production and

import/export licenses in Guernsey

2020

• First ICA test crops started in Colombia

SPRING:• Issuance of Guernsey licenses• Completion of ICA seed tests in

Colombia• Begin renovations to Guernsey property

FALL:• Plant first commercial crops in Colombia• Plant first commercial crops in Guernsey• Process first commercial crops in

Colombia• Export first extractions from Colombia to

Guernsey and UK

www4clabs.ca

4C LABS Cap TableBASIC SHARES OUTSTANDING 25,010,000RSUs 1 750,000RSUS 2 1,000,000

TOTAL RSUs 1,750,000FULLY DILUTED SHARES 28,510,000

*Board of Directors, Board of Advisors and Management own 85% of 4C Labs

www4clabs.ca

Item CostSeed Testing $88,000Product Formulations $240,000Guernsey $24,000Grower & Operations Salaries $45,000Legal Fees & Licensing $78,000Administrative Costs $16,000Travel Expenses $19,000Conference Costs $12,000Accounting $4,800Contingency $22,200TOTAL $549,000

www.4clabs.ca

Use of FundsCurrent Value Pre-Money is $6,690,000.

Current Offering at $0.25/share.

4C LABS financial strategy involves a path to the public markets. The CSX in Canada provides an excellent vehicle for funding future growth and allowing early stage investors to re-balance portfolios.

Social Responsibility4C Labs is committed to creating numerous long-term jobs in the countries in which we operate, building community partnerships and supporting cultural development.

www.4clabs.ca

Meet the Core Team

www.4clabs.ca

David Farquharson Greg Dobbin James SmithExecutive Chairman & Founder CEO CRO

Dave has been involved in the investment banking business for over 20 years, raising capital for mining, oil & gas, and alternative energy companies. His focus in the past 6 years has been on venture and early stage companies.

Graduating from Bishop’s University in Business, Greg has spend the last 20 years in film production which has taken him around the globe. He uses his international work experience and connections to ramp up operations for 4C LABS in multiple jurisdictions.

After graduating from Bishop’s University in Political Science, James went on to pursue a career in commercial real estate and development. James has a keen ability to find key partners, develop long-term relationships, and create sales pipelines.

Advisors and Board Members

www.4clabs.ca

Dr. Michael BarnesChief Medical Advisor

Educated at the University of Bristol, Dr. Barnes has been recognized worldwide for his contributions in the field of neurology. Dr. Barnes currently runs the Academy of Medical Cannabis, a non-profit organization that educates and provides government certification for doctors in the field of Medical Cannabis. Dr. Barnes also owns and runs The Medical Cannabis clinics in the UK.

Sean CharlandBoard Member

Mr. Charland is a seasoned communications professional, experienced in raising capital and marketing resource exploration projects. His large network of contacts within the financial community extends across North America and Europe. Mr. Charland is currently a Director of Zimtu Capital Corp. He is also a Director of Eye CarrotInnovations, Arctic Star Explorations on and Director of Maple Gold Mines.

ContactDavid Farquharson, Executive Chairman and Founder

1-416-662-4183davidf@4clabs.ca

Canadian Office:4C LABS365 Bay Street, Suite 800Toronto ONCANADA M5H 2V1

www.4clabs.ca